Evidence map›Paper›PMID 30150938›Full record

ArticleFrontiers in pharmacology2018

Wogonin Attenuates Isoprenaline-Induced Myocardial Hypertrophy in Mice by Suppressing the PI3K/Akt Pathway.

Weichun Qian, Dongsheng Yu, Jia Zhang, Qiaoyun Hu, Chuanfeng Tang, Peiyu Liu, Peng Ye, Xiaoli Wang, Qiu Lv, Minglong Chen and 1 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Weichun QianDepartment of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Dongsheng YuDepartment of Pharmacology, School of Basic Medical Science, Nanjing Medical University, Nanjing, China.
Jia ZhangDepartment of Pharmacology, School of Basic Medical Science, Nanjing Medical University, Nanjing, China.
Qiaoyun HuDepartment of Pharmacology, School of Basic Medical Science, Nanjing Medical University, Nanjing, China.
Chuanfeng TangDepartment of Pharmacology, School of Basic Medical Science, Nanjing Medical University, Nanjing, China.
Peiyu LiuDepartment of Pharmacology, School of Basic Medical Science, Nanjing Medical University, Nanjing, China.
Peng YeDepartment of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiaoli WangDepartment of Pharmacology, School of Basic Medical Science, Nanjing Medical University, Nanjing, China.
Qiu LvDepartment of Pharmacology, School of Basic Medical Science, Nanjing Medical University, Nanjing, China.
Minglong ChenDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Liang ShengDepartment of Pharmacology, School of Basic Medical Science, Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many studies have focused on identifying therapeutic targets of myocardial hypertrophy for the treatment of correlative cardiac events. Wogonin is a natural flavonoid compound that displays a potent anti-hypertrophic effect. Knowledge of its pharmacological mechanisms might reveal an effective way to search for therapeutic targets. Myocardial hypertrophy was replicated by the subcutaneous implantation of an isoprenaline mini-pump in mice or isoprenaline treatment of H9C2 cells. Pathologic changes in cardiac structure were assessed by echocardiographic and histological examinations. The signaling transduction in hypertrophy-promoting pathways and the genes involved were detected by western blot and RT-qPCR. Wogonin significantly attenuated isoprenaline-induced myocardial hypertrophy

Indexed as

myocardial hypertrophyNedd4lPik3caubiqutinationwogonin

Identifiers

PMID30150938
PMCPMC6099096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.